The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment
Open Access
- 1 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 17 (8) , 1651-1664
- https://doi.org/10.1002/ibd.21538
Abstract
Background. Cannabinoids are known to reduce intestinal inflammation. Atypical cannabinoids produce pharmacological effects via unidentified targets. WKeywords
This publication has 57 references indexed in Scilit:
- Requirement of cannabinoid CB1 receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projectionsEuropean Journal of Neuroscience, 2010
- N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptorBMC Neuroscience, 2010
- The therapeutic potential of novel cannabinoid receptorsPharmacology & Therapeutics, 2009
- GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M currentProceedings of the National Academy of Sciences, 2008
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007
- Novel cannabinoid receptorsBritish Journal of Pharmacology, 2007
- Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory painBritish Journal of Pharmacology, 2007
- The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effectsBritish Journal of Pharmacology, 2007
- Lipopolysaccharide: A p38 MAPK-Dependent Disrupter of Neutrophil ChemotaxisMicrocirculation, 2005